Okyo Pharma clinical trials we track

Check company identity source

Phase 3 1 trial

Phase 2 2 trials

Drugs in these trials

Names as written in the registry records.

Latest recorded trial changes

Filters
Clear filters

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: The change from baseline at Week 12 in ocular pain assessed by VAS score. Description: Evaluate the efficacy and safety of urcosimod 0.05% as compared to placebo instilled 4 times/day in participants who have a documented ocular history of symptoms of neuropathic corneal pain. Time frame: From baseline (time of randomization) compared to Week 12.. After: Measure: The change from baseline at Week 12 in ocular pain assessed by Visual Analogue Scale (0-10) score. (Score of 10 is "worst possible pain".) Description: Evaluate the efficacy and safety of urcosimod 0.05% as compared to placebo instilled 4 times/day in participants who have a documented ocular history of symptoms of neuropathic corneal pain. Time frame: From baseline (time of randomization) compared to Week 12..

Check registry source